....to tests for guiding adjuvant chemotherapy decisions in early breast cancer. The final assessment determination is now published for gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. It is approval with research for Oncotype (but only with a patient access scheme) and only in research for the other tests.
The Assessment Group was ScHARR-TAG, with Sue Ward, Alison Scope, Rachid Rafia, Abdullah Pandor, Sue Harnan and Pippa Evans doing all the work.
